Comparing two stent graft devices for abdominal aortic aneurysm repair
Compares the Alto stent graft with approved grafts in people with abdominal aortic aneurysm.
Key facts
- Who runs it
- Endologix
- Where
- Allentown, Boston, Cleveland, Columbia, Columbus, Detroit, Fayetteville, Galveston, Houston, Huntsville, Iowa City, Jacksonville, Kingsport, La Jolla, Lakeland, Little Rock, Louisville, Miami, New York, Newark, Norfolk, Philadelphia, Pittsburgh, Portland, San Diego, Staten Island, Tucson, and Washington D.C., United StatesSee the 29 sites
- Trial code
- Registry title
- JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
- Status
- Recruiting
- People taking part
- 450 people, planned
- Started
- 20 Sept 2021
- Expected to end
- Mar 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Alto Abdominal Stent Graft System
- FDA Approved EVAR AAA Graft Systems
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an abdominal aortic aneurysm below the kidneys that has not burst. The doctor must judge they can have repair through the blood vessels (EVAR) with the trial devices.
- Age
- 21 years and older
- Sex
- All sexes
- Disease stage
- Unruptured infrarenal abdominal aortic aneurysm (a bulge in the main belly artery, below the kidneys, that has not burst). Life expectancy of at least 2 years.
- Earlier treatment
- People who already had EVAR, or need repair of an earlier EVAR that failed, cannot join.
Main reasons for not taking part
- Taking part in another trial that has not reached its main goal yet
- Known allergy to any part of the device
- Pregnancy
- Known connective tissue disorder or known active infection
- Earlier EVAR repair
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Adult age 21 and older
- Subjects with minimum of 2 year life expectancy
- Subjects have signed the informed consent document
- Subjects with unruptured infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices
- Patient must be able and willing to comply with all required follow-up exams
Who cannot take part
- Subjects with pre-existing EVAR, i.e., in need of repair/intervention of a previously failed EVAR
- Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations
- Known allergy to any of the device components
- Known connective tissue disorders
- Known active infection
- Currently participating in another trial where the primary endpoint has not been reached yet
- Pregnant (females of childbearing potential only)
Where in United States
- Lehigh Valley Health NetworkAllentown, United StatesContact: Deborah MankosTaking people
- Tufts Medical CenterBoston, United StatesContact: Gaurav DasTaking people
- The Cleveland Clinical FoundationCleveland, United StatesContact: Larissa Schaaf, RNTaking people
- University of MissouriColumbia, United StatesContact: Jennifer RandolphTaking people
- The Ohio State UniversityColumbus, United StatesContact: Noel DeSistoNo longer taking part
- Henry Ford HospitalDetroit, United StatesContact: Noel DeSistoNo longer taking part
- Washington Regional Medical CenterFayetteville, United StatesTaking people
- The University of Texas Medical Branch at GalvestonGalveston, United StatesContact: Sana MalikTaking people
- Houston Methodist Research InstituteHouston, United StatesContact: Solange BasagoitiaTaking people
- Huntsville HospitalHuntsville, United StatesContact: Noel DeSistoNo longer taking part
- University of Iowa Hospitals and ClinicsIowa City, United StatesContact: Noel DeSistoNo longer taking part
- Jacksonville Center for Clinical ResearchJacksonville, United StatesContact: Lisa JosephTaking people
- Wellmont Cardiology ServicesKingsport, United StatesContact: Joshua LesterTaking people
- The Regents of the University of California - San DiegoLa Jolla, United StatesContact: Kathleen GrohTaking people
- Radiology and Imaging SpecialistsLakeland, United StatesContact: Eve JohnsonTaking people
- Central Arkansas Veterans Healthcare SystemLittle Rock, United StatesContact: Sandra BrockTaking people
- University of LouisvilleLouisville, United StatesContact: Leslie HaysleyTaking people
- Baptist Hospital of Miami, Miami Cardiac and Vascular InstituteMiami, United StatesContact: David FernandezTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Jack WaitzTaking people
- Newark Beth Israel Medical CenterNewark, United StatesContact: Debra CookTaking people
- Sentara HospitalsNorfolk, United StatesContact: Kara Wiggins, MSN, RNTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Thomas HebertTaking people
- Allegheny Health NetworkPittsburgh, United StatesContact: Sheila BernardiniTaking people
- Oregon Health Sciences UniversityPortland, United StatesContact: Amie LorischTaking people
- U.S. Department of Veterans Affairs, VA Portland Health Care SystemPortland, United StatesContact: Jin KimTaking people
- Veterans Affairs San Diego Healthcare SystemSan Diego, United StatesContact: Annalicia VargasTaking people
- Feinstein Institutes for Medical Research (Staten Island University Hospital/Northwell Health)Staten Island, United StatesContact: Alexandra PanteaTaking people
- University of ArizonaTucson, United StatesContact: Karen SanchezTaking people
- MedStar Washington Hospital CenterWashington D.C., United StatesContact: Kassaye SesabaTaking people
About the trial
What the trial wants to find out
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.
Read full original descriptionShow less
Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
The 2 groups in the trial
- Alto Abdominal Stent Graft SystemTreatment being tested
Subjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.
- ComparatorsExisting treatment, for comparison
Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.
Treatment: FDA Approved EVAR AAA Graft Systems
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
- Plain-language title
- Comparing two stent graft devices for abdominal aortic aneurysm repairGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 September 2026